How Long to Continue Surveillance in Patients Following ‘Curative Resection’ of Primary Small Bowel Tumors? Abstract #375

Introduction: Around 40-50% of patients with small bowel (SB) NETs have metastatic disease at the time of presentation. The majority of the remainder proceed to surgery for attempted curative resection. The optimal duration of surveillance post ‘curative surgical’ resection of primary SB NETs is unknown.
Aim(s): A retrospective analysis to determine the time to development of metastases following resection of primary tumor +/- mesenteric disease in an attempted curative resection.
Materials and methods: The data was analysed using Microsoft Excel and Graph Pad Prizm 5.0. One-hundred and thirty-eight patients with SB NETs were identified, of these the primary had been resected in 100 patients. Only patients in whom current disease state was known were included.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Raj Srirajaskanthan

To read results and conclusion, please login ...

Further abstracts you may be interested in

#14 Radioguided surgery in NET: First impression with Ga-68 labeled somatostatin analogues
Introduction: Neuroendocrine tumors (NET) constitute a heterogenous group of neoplasms. The development of Gallium-68-labeled somatostatin analogues, such as DOTA-NOC or DOTA-TOC, PET/CT have dramatically improved the diagnosis of neuroendocrine tumors. Surgery remains the treatment of choice for localized disease as well as metastatic disease. The aims of surgery are: improvement of symptoms, reduction of tumor mass / burden and to give better quality of life to patients. Recurrent laparotomies often lead to multiple adhesions and altered anatomy. So it is increasingly difficult for imaging physicians and surgeons to separate non-malignant from malignant tissue.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Daniel Kaemmerer
#376 Resection of Primary Tumor Improves Survival in Small Bowel Neuroendocrine Tumors: A Single Center Experience
Introduction: Small bowel neuroendocrine tumors are uncommon tumors with an incidence of <0.5-1 per 100,000 population/year. We report on the survival rates of patients who had the primary tumor resected, to see whether primary tumor removal improves outcome.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Raj Srirajaskanthan
#377 Survival and Cause of Death in Patients with Small Bowel Neuroendocrine Tumors
Introduction: Small bowel neuroendocrine tumors (SB NETs) have a reported incidence of approximately 0.5-1 per 100 000 population/yr.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Raj Srirajaskanthan
#378 Does TNM Staging Classification Predict Survival in Patients with Small Bowel Neuroendocrine Tumors?
Introduction: Small bowel (SB) NETs are regarded as relatively indolent cancers. ENETS has published TNM staging. This study aims to demonstrate whether the TNM stage predicts survival in this cohort of patients.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Raj Srirajaskanthan
Keywords: TNM, survival
#575 Does the ENETS TNM staging criteria predict survival in patients with small bowel neuroendocrine tumours?
Introduction: A TNM staging system was designed by ENETS to stage small bowel NETs .(SBNETs)
Conference: 10th Annual ENETS Conference (2013)
Category: Clinical
Presenting Author: Dr Rajaventhan Srirajaskanthan
Keywords: Staging